Literature DB >> 6953747

Studies on acute toxicity and drug levels of citalopram in the dog.

V Boeck, K F Overø, O Svendsen.   

Abstract

Electrocardiographic and haemodynamic changes have been studied in conscious dogs after a sublethal oral dose (20 mg . kg-1) of citalopram. Furthermore, the effects of continuous intravenous infusion of citalopram (10 mg . kg-1 per hour) have been studied in conscious and anesthetized dogs. The findings have been related to plasma levels of citalopram. Severe convulsive attacks occurred in conscious dogs after infusion of 21.3 or 26.5 mg . kg-1 and after the oral dose. The convulsions were successfully treated with diazepam. In contrast convulsions were not seen in the anesthetized dogs. They died from respiratory arrest after infusion of 42.2 or 61.3 mg . kg-1. Atrioventricular and intraventricular conduction was unchanged and electrocardiographic changes were negligible. Sinus tachycardia which could be reversed by diazepam and moderate haemodynamic changes were seen. Since no electrocardiographic changes were seen in conscious dogs even during pauses in the convulsive seizure it is concluded that citalopram does not exert cardiotoxic effects in the dog. Good correlation was found between general clinical findings and citalopram levels in plasma. Conscious dogs were exposed to drug levels exceeding those of the average patient by a factor of about 20, while anesthetized dogs had considerable higher concentrations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953747     DOI: 10.1111/j.1600-0773.1982.tb00959.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  10 in total

1.  Kinetics of citalopram in elderly patients.

Authors:  K Fredericson Overø; B Toft; L Christophersen; J P Gylding-Sabroe
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels.

Authors:  V Boeck; A Jørgensen; K Fredricson Overø
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 3.  Citalopram and cardiac toxicity.

Authors:  M J Cooke; W S Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

Review 4.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels.

Authors:  L Bjerkenstedt; L Flyckt; K F Overø; O Lingjaerde
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest.

Authors:  Asim F Tarabar; Robert S Hoffman; Lewis Nelson
Journal:  J Med Toxicol       Date:  2008-06

7.  The effects of citalopram (Lu 10-171) on the serotonin (5-HT) uptake kinetics in platelets from endogenously depressed patients.

Authors:  H Beving; L Bjerkenstedt; R Malmgren; P Olsson; G Unge
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

8.  Citalopram, a selective serotonin reuptake inhibitor: clinical antidepressive and long-term effect--a phase II study.

Authors:  O L Pedersen; P Kragh-Sørensen; M Bjerre; K F Overø; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Predictive factors for generalized seizures after deliberate citalopram overdose.

Authors:  W Stephen Waring; Julie A Gray; Ann Graham
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

10.  Clinical and biochemical effects of citalopram, a selective 5-HT reuptake inhibitor--a dose-response study in depressed patients.

Authors:  L Bjerkenstedt; G Edman; L Flyckt; L Hagenfeldt; G Sedvall; F A Wiesel
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.